xbb .1.5-加利福尼亚州和路易斯安那州5-17岁儿童适应单剂疫苗的摄取和有效性。

IF 3.5 2区医学 Q1 PEDIATRICS

Journal of Pediatrics Pub Date : 2025-08-14 DOI:10.1016/j.jpeds.2025.114778

Kathleen M. Andersen PhD, MSc , Maria D. McColgan MD , Jazmine S. Mateus MPH , Tiange Yu MPH , Anan Zhou MPH , Laura Puzniak PhD , Santiago M.C. Lopez MD

{"title":"xbb .1.5-加利福尼亚州和路易斯安那州5-17岁儿童适应单剂疫苗的摄取和有效性。","authors":"Kathleen M. Andersen PhD, MSc , Maria D. McColgan MD , Jazmine S. Mateus MPH , Tiange Yu MPH , Anan Zhou MPH , Laura Puzniak PhD , Santiago M.C. Lopez MD","doi":"10.1016/j.jpeds.2025.114778","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To assess BNT162b2 XBB.1.5-adapted COVID-19 vaccine uptake and effectiveness in children aged 5-17 years against emergency department (ED) encounters, urgent care (UC) visits, and hospital admissions.</div></div><div><h3>Study design</h3><div>We conducted a retrospective cohort study using HealthVerity claims tokenized to California and Louisiana state vaccine registries. Children were followed using a time-varying exposure definition, with vaccinated time ≥14 days after vaccination, from September 25, 2023 through March 31, 2024. Incidence and incidence rates were calculated for vaccinated and unvaccinated time. Time-dependent Cox models were used to estimate adjusted hazard ratios, with percent vaccine effectiveness calculated as (1 – hazard ratio)∗100.</div></div><div><h3>Results</h3><div>Of 2 449 261 children aged 5-17 years who met inclusion criteria, 34 389 (1.4%) received an XBB.1.5-adapted BNT162b2 vaccine. Vaccination uptake was higher in California than Louisiana and increased with age. Half (51.2%) of children who received the XBB.1.5-adapted vaccine had received a 2022-2023 season BA.4/5 bivalent COVID-19 vaccine. In contrast, the majority (66.0%) of XBB.1.5 unvaccinated children had not received any prior COVID-19 vaccine. For all measured outcomes, the XBB vaccinated children had significantly lower incidence rates compared with those who did not receive any XBB vaccine. There were no COVID-19 associated hospitalizations in the vaccinated group. Adjusted vaccine effectiveness among children aged 5-17 years was 63% (95% CI: 39%–77%) against COVID-19-associated ED/UC encounters with similar results stratified by age and among varying outcomes.</div></div><div><h3>Conclusion</h3><div>BNT162b2 XBB.1.5-adapted formulations provided significant protection in children aged 5-17 years against COVID-19 associated hospitalization and ED or UC visits.</div></div><div><h3>Clinical Trial Registration</h3><div><span><span>NCT06199934</span><svg><path></path></svg></span> (<span><span>https://clinicaltrials.gov/study/NCT06199934</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":54774,"journal":{"name":"Journal of Pediatrics","volume":"286 ","pages":"Article 114778"},"PeriodicalIF":3.5000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BNT162b2 XBB.1.5-Adapted Single Dose Vaccine Uptake and Effectiveness in Children Aged 5-17 Years Using Linked Claims and Vaccine Registries in California and Louisiana\",\"authors\":\"Kathleen M. Andersen PhD, MSc , Maria D. McColgan MD , Jazmine S. Mateus MPH , Tiange Yu MPH , Anan Zhou MPH , Laura Puzniak PhD , Santiago M.C. Lopez MD\",\"doi\":\"10.1016/j.jpeds.2025.114778\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>To assess BNT162b2 XBB.1.5-adapted COVID-19 vaccine uptake and effectiveness in children aged 5-17 years against emergency department (ED) encounters, urgent care (UC) visits, and hospital admissions.</div></div><div><h3>Study design</h3><div>We conducted a retrospective cohort study using HealthVerity claims tokenized to California and Louisiana state vaccine registries. Children were followed using a time-varying exposure definition, with vaccinated time ≥14 days after vaccination, from September 25, 2023 through March 31, 2024. Incidence and incidence rates were calculated for vaccinated and unvaccinated time. Time-dependent Cox models were used to estimate adjusted hazard ratios, with percent vaccine effectiveness calculated as (1 – hazard ratio)∗100.</div></div><div><h3>Results</h3><div>Of 2 449 261 children aged 5-17 years who met inclusion criteria, 34 389 (1.4%) received an XBB.1.5-adapted BNT162b2 vaccine. Vaccination uptake was higher in California than Louisiana and increased with age. Half (51.2%) of children who received the XBB.1.5-adapted vaccine had received a 2022-2023 season BA.4/5 bivalent COVID-19 vaccine. In contrast, the majority (66.0%) of XBB.1.5 unvaccinated children had not received any prior COVID-19 vaccine. For all measured outcomes, the XBB vaccinated children had significantly lower incidence rates compared with those who did not receive any XBB vaccine. There were no COVID-19 associated hospitalizations in the vaccinated group. Adjusted vaccine effectiveness among children aged 5-17 years was 63% (95% CI: 39%–77%) against COVID-19-associated ED/UC encounters with similar results stratified by age and among varying outcomes.</div></div><div><h3>Conclusion</h3><div>BNT162b2 XBB.1.5-adapted formulations provided significant protection in children aged 5-17 years against COVID-19 associated hospitalization and ED or UC visits.</div></div><div><h3>Clinical Trial Registration</h3><div><span><span>NCT06199934</span><svg><path></path></svg></span> (<span><span>https://clinicaltrials.gov/study/NCT06199934</span><svg><path></path></svg></span>).</div></div>\",\"PeriodicalId\":54774,\"journal\":{\"name\":\"Journal of Pediatrics\",\"volume\":\"286 \",\"pages\":\"Article 114778\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatrics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0022347625003191\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022347625003191","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

摘要

目的：评估5-17岁儿童对急诊（ED）就诊、急诊（UC）就诊和住院的BNT162b2 xbb .1.5适应COVID-19疫苗的摄取和有效性。研究设计：我们进行了一项回顾性队列研究，使用HealthVerity声明标记为加利福尼亚州和路易斯安那州的疫苗登记处。采用时变暴露定义对2023年9月25日至2024年3月31日期间接种疫苗时间≥14天的儿童进行随访。计算接种疫苗和未接种疫苗时间的发病率和发病率。使用时变Cox模型估计调整后的危险比（HR），疫苗有效性百分比（VE）计算为(1 - HR)*100。结果：在符合纳入标准的2,449,261名5-17岁儿童中，34,389名（1.4%）接种了xbb .1.5-适应型BNT162b2疫苗。加利福尼亚州的疫苗接种率高于路易斯安那州，并且随着年龄的增长而增加。接受xbb .1.5适应疫苗的儿童中，有一半（51.2%）接种了2022-2023季BA.4/5二价COVID-19疫苗。相比之下，大多数（66.0%）未接种XBB.1.5疫苗的儿童此前未接种过COVID-19疫苗。对于所有测量结果，接种XBB疫苗的儿童与未接种任何XBB疫苗的儿童相比，发病率显著降低。接种疫苗组中没有与COVID-19相关的住院治疗。与covid -19相关的ED/UC遭遇相比，5-17岁儿童的调整VE为63%(95%可信区间[CI]: 39-77%)，按年龄分层和不同结局的结果相似。结论：BNT162b2 xbb .1.5适应配方可显著保护5-17岁儿童免受COVID-19相关住院和ED或UC就诊。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

BNT162b2 XBB.1.5-Adapted Single Dose Vaccine Uptake and Effectiveness in Children Aged 5-17 Years Using Linked Claims and Vaccine Registries in California and Louisiana

Objective

To assess BNT162b2 XBB.1.5-adapted COVID-19 vaccine uptake and effectiveness in children aged 5-17 years against emergency department (ED) encounters, urgent care (UC) visits, and hospital admissions.

Study design

We conducted a retrospective cohort study using HealthVerity claims tokenized to California and Louisiana state vaccine registries. Children were followed using a time-varying exposure definition, with vaccinated time ≥14 days after vaccination, from September 25, 2023 through March 31, 2024. Incidence and incidence rates were calculated for vaccinated and unvaccinated time. Time-dependent Cox models were used to estimate adjusted hazard ratios, with percent vaccine effectiveness calculated as (1 – hazard ratio)∗100.

Results

Of 2 449 261 children aged 5-17 years who met inclusion criteria, 34 389 (1.4%) received an XBB.1.5-adapted BNT162b2 vaccine. Vaccination uptake was higher in California than Louisiana and increased with age. Half (51.2%) of children who received the XBB.1.5-adapted vaccine had received a 2022-2023 season BA.4/5 bivalent COVID-19 vaccine. In contrast, the majority (66.0%) of XBB.1.5 unvaccinated children had not received any prior COVID-19 vaccine. For all measured outcomes, the XBB vaccinated children had significantly lower incidence rates compared with those who did not receive any XBB vaccine. There were no COVID-19 associated hospitalizations in the vaccinated group. Adjusted vaccine effectiveness among children aged 5-17 years was 63% (95% CI: 39%–77%) against COVID-19-associated ED/UC encounters with similar results stratified by age and among varying outcomes.

Conclusion

BNT162b2 XBB.1.5-adapted formulations provided significant protection in children aged 5-17 years against COVID-19 associated hospitalization and ED or UC visits.

Clinical Trial Registration

NCT06199934 (https://clinicaltrials.gov/study/NCT06199934).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Pediatrics 医学-小儿科

CiteScore

6.00

自引率

2.00%

发文量

696

审稿时长

31 days

期刊介绍： The Journal of Pediatrics is an international peer-reviewed journal that advances pediatric research and serves as a practical guide for pediatricians who manage health and diagnose and treat disorders in infants, children, and adolescents. The Journal publishes original work based on standards of excellence and expert review. The Journal seeks to publish high quality original articles that are immediately applicable to practice (basic science, translational research, evidence-based medicine), brief clinical and laboratory case reports, medical progress, expert commentary, grand rounds, insightful editorials, “classic” physical examinations, and novel insights into clinical and academic pediatric medicine related to every aspect of child health. Published monthly since 1932, The Journal of Pediatrics continues to promote the latest developments in pediatric medicine, child health, policy, and advocacy. Topics covered in The Journal of Pediatrics include, but are not limited to: General Pediatrics Pediatric Subspecialties Adolescent Medicine Allergy and Immunology Cardiology Critical Care Medicine Developmental-Behavioral Medicine Endocrinology Gastroenterology Hematology-Oncology Infectious Diseases Neonatal-Perinatal Medicine Nephrology Neurology Emergency Medicine Pulmonology Rheumatology Genetics Ethics Health Service Research Pediatric Hospitalist Medicine.